BALTIMORE, December 1, 2022 /PRNewswire/ — Haystack Oncology (“Haystack”), an oncology company applying next-generation circulating tumor DNA (ctDNA) detection technology to optimize minimal residual disease (MRD) testing and better illuminate decisions regarding treatment, today announced the appointment of Joel Kaufmann as chief financial officer. Mr. Kaufman joins Haystack with over a decade of experience spanning business development, investment banking and finance. Mr. Kaufman will lead Haystack’s financial operations and implement strategic initiatives to support commercialization of the company’s best-in-class MRD test.
“Joel’s experience and insight into clinical diagnostics and biopharmaceuticals will be invaluable to Haystack during this exciting time of corporate growth and development,” said Dan Edelstein, President and CEO of Haystack Oncology. “Over the coming year, we will commercialize Haystack’s best-in-class MRD test, which has the potential to significantly improve the accuracy of treatment decisions for patients with solid tumors. As Chief Financial Officer, Joel will be instrumental in our preparation for this milestone and in our overall business development initiatives. »
Mr. Kaufman has overseen the financial and business operations of several life science companies. Most recently, he served as Vice President of Finance and Corporate Development at Sema4, an AI-focused precision medicine company. Previously, Mr. Kaufman spent nearly four years in multiple roles, culminating as Chief Commercial Officer, at Navidea Biopharmaceuticals. He was also an equity research analyst at Goldman Sachs, covering the life science tools, diagnostics and medical technology sectors. Mr. Kaufman holds an MBA from Northwestern University Kellogg School of Management and a BA from University of Pennsylvania.
“I am proud to join the exceptional team at Haystack Oncology as we work together to achieve our important mission of providing better MRD tests to improve patient outcomes and enable superior clinical management and therapeutic development,” said Mr. Kaufman said. “Haystack has demonstrated the potential to have a major impact on optimizing treatments for patients living with solid tumors, and I am delighted to join the company at this pivotal stage.
Haystack emerged from stealth last month with a $56 million Series A fundraising led by Catalio Capital Management. The company plans to market its best diagnostic test in 2023 for use in solid tumors. Haystack also recently announced plans to move into a 20,000 square foot facility at the City Garage Science & Technology Center in South of Baltimore to expand testing services to achieve their business goals.
About Haystack Oncology
Haystack Oncology uses the next generation of circulating tumor DNA (ctDNA) detection technology to see through the noise and uncover the lowest levels of ctDNA in the blood to signal residual, recurrent or resistant disease. Founded in 2021 by pioneers in cancer genomics Bert Vogelstein, Ken Kinzlerand Nick Papadopoulos of Johns Hopkins UniversityHaystack’s team of liquid biopsy experts have developed a MRD test taking into account the tumor this is best placed to provide the right treatment to the right person at the right time. Haystack is based in Baltimore, MDUnited States, and has research facilities in Hamburg, Germany. Learn more at haystackoncology.com.
SOURCE Haystack Oncology